Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients
2024

Galectin Levels and Kidney Damage in Multiple Myeloma Patients

Sample size: 47 publication Evidence: high

Author Information

Author(s): Carvalho Lidiane Vasconcelos do Nascimento, Assis Reijane Alves, Montenegro Claudio, da Rosa Michelle Melgarejo, Pereira Michelly Cristiny, Pitta Maira Galdino da Rocha, de Melo Rêgo Moacyr Jesus Barreto, Capasso Domenica, Pedone EmiliaMaria, Di Gaetano Sonia

Primary Institution: Research Center for Therapeutic Innovation (NUPIT-SG), Federal University of Pernambuco, Recife, Brazil

Hypothesis

This study aimed to assess the plasma levels of galectins in newly diagnosed multiple myeloma patients and explore their correlation with clinical parameters.

Conclusion

Elevated galectin levels are indicative of disease aggressiveness and renal impairment in multiple myeloma patients.

Supporting Evidence

  • Plasma levels of galectins-3, -7, and -9 were significantly higher in multiple myeloma patients compared to the control group.
  • Three clusters of multiple myeloma patients were identified based on galectin plasma levels, with one cluster associated with a worse prognosis.
  • A strong positive correlation was found between galectin-1, -4, and -7 levels and markers of kidney function.
  • Galectin-9 showed high accuracy in distinguishing multiple myeloma patients from healthy controls (AUC = 0.931).
  • Elevated galectin levels were indicative of disease aggressiveness and renal impairment in multiple myeloma patients.

Takeaway

The study found that higher levels of certain proteins called galectins in the blood can show how serious the disease is and how it affects the kidneys in patients with multiple myeloma.

Methodology

Plasma levels of galectins were measured using ELISA in blood samples from newly diagnosed multiple myeloma patients.

Participant Demographics

Among the 47 patients, there was a slight male predominance, with a median age of 60 years.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI: 0.875–0.988

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/ijms252413499

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication